CSIMarket
 
Unicycive Therapeutics Inc   (UNCY)
Other Ticker:  
 
 


 
 UNCY $1.4500 $-0.0700 -4.61%

 Volume (M): 221   Open : 1.53    52 Wk Avg :  1.10

 
 UNCY $1.4500 $-0.0700 -4.61%

 Volume (M): 221   Open : 1.53    52 Wk Avg :  1.10




UNCY Today's High: $1.555 UNCY Shares One Week Perf: 2.11 %
UNCY Today's Low: $ 1.42 UNCY Shares 30 Day Performance: -8.23 %
Number of UNCY Shares Traded (M): 221 UNCY Share Price 52 Wk High: $ 2.29
Value of UNCY's Shares Traded (M$): $ 321 UNCY Share Price 52 Wk Avg: $1.10
Share Price at the Open: $1.53 UNCY's Share Price 52 Wk Low: $0.47



  News about Unicycive Therapeutics Inc's Stock Splits and Dividends

Unicycive Announces $50 Million Private Placement: Expanding Investor Base and Progressing towards Key Milestones


In an exciting move for Unicycive Therapeutics Inc, the company has recently announced a successful private placement that has secured $50 million in investment. This funding round was led by new investors Octagon Capital and Great Point Partners, LLC, with participation from other new and existing investors, including Logos Capital, Nantahala Capital, SilverArc Capital, Velan Capital, Vivo Capital, and Walleye Capital.
This significant private placement not only strengthens Unicycive's financial position but also highlights the growing confidence in the company and its potential. With an expanded investor base now supporting the company, Unicycive is well-positioned to execute its strategic plans and achieve key milestones.

OLC Aims to Revolutionize the Multibillion-Dollar Hyperphosphatemia Market: Topline Data from Pivotal Trial Expected in Q2 2024



In the world of biopharmaceuticals, research and development efforts are constantly underway to address pressing medical needs and advance patient care. One such endeavor is currently being pursued by OLC, a leading pharmaceutical company focused on tackling hyperphosphatemia. With fresh topline data from their pivotal trial anticipated in the second quarter of 2024, OLC is poised to make a significant impact in the multibillion-dollar market for hyperphosphatemia treatments. This article delves into the cutting-edge developments surrounding OLC's novel therapy and its potential to revolutionize the treatment landscape for this challenging condition.
Background and Significance of Hyperphosphatemia:
Hyperphosphatemia refers to an excessive level of phosphate in the blood, typically caused by impaired kidney function. While it may not appear as prevalent as some well-known diseases, hyperphosphatemia poses a significant threat to the estimated 10% of global population suffering from chronic kidney disease (CKD). Elevated phosphate levels contribute to the development of numerous complications, including cardiovascular diseases, bone abnormalities, and increased mortality rates in CKD patients. Consequently, addressing hyperphosphatemia represents a crucial imperative for the medical community.





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com